Caribou Biosciences, Inc. is 10% Owner at Intellia Therapeutics, Inc. (NTLA). They have made 1 open-market trade across 1 company since 2018, most recently 2018-01-29.
CIK 0001619856
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NTLA | 3,994,355 | $45.6M |
Shares reported on the most recent Form 4, priced at the 2018-01-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NTLA | SELL | 2018-01-29 | 2018-01-30 | $26.78 | $29.5M | -10.0% | -3.0% | -23.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.